Year: 2003
Type: review
Abstract: Amyotrophic lateral sclerosis (ALS) is a relentless fatal paralytic disorder confined to the voluntary motor system (1).Its prevalence is about three to five in 100,000 individuals, making it the most frequent paralytic disease in adults.Although ALS can strike anyone at any age, generally the onset of the disease is in the fourth or fifth decade of life.Common clinical features of ALS include muscle weakness, fasciculations, brisk (or depressed) reflexes, and extensor plantar responses.Even though motor deficit usually predominates in the limbs, bulbar enervation can also be severely affected, leading to atrophy of the tongue, dysphagia, and dysarthria.Other cranial nerves (e.g., oculomotor nerves) are usually spared.The progressive decline of muscular function results in paralysis, speech and swallowing disabilities, emotional disturbance, and, ultimately, respiratory failure causing death among the vast majority of ALS patients within 2-5 years after the onset of the disease.Pathologically, ALS is characterized by a loss of upper motor neurons in the cerebral cortex and of the lower motor neurons in the spinal cord.Often, there is also a profound degeneration of the corticospinal tracts, which is most evident at the level of the spinal cord.The few remaining motor neurons are generally atrophic, and many demonstrate abnormal accumulation of neurofilament, in both their cell bodies and axons.To date, only a few approved treatments (e.g., mechanical ventilation and riluzole) prolong survival in ALS patients to some extent.However, the development of more effective neuroprotective therapies remains impeded by our limited knowledge of the actual mechanisms by which neurons die in ALS, and of how the disease progresses and propagates.
DOI: 10.1172/jci17610
Authors: Christelle Guégan, Serge Przedborski
Institution: Columbia University
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2020935865
